Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Disc Medicine Inc.

Jefferies analyst maintained a Buy rating on Disc Medicine today and set a price target of $154.00. In a report released today, H.C. Wainwright als...

Jefferies Keeps Their Buy Rating on Disc Medicine (IRON)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Disc Medicine, with a price target of $153.00. Acc...

Cantor Fitzgerald Sticks to Its Buy Rating for Disc Medicine (IRON)

Disc Medicine ( ($IRON) ) has shared an announcement. On December 7, 2025, Disc Medicine held a conference call to discuss its data presented at th...

Disc Medicine Advances Bitopertin in FDA Pilot Program

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings from Top Wall Street ...

3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Janux Therapeutics Inc (JANX – Research Report) and ...

Analysts’ Top Healthcare Picks: Janux Therapeutics Inc (JANX), Disc Medicine (IRON)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Disc Medicine today and set a price target of $118.00. Tsao covers the Healthcare s...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRON	$91.85	-1.87%	515.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRON	$91.85	-1.9%	515.59K
3
4
5
6

IRON

IRON

Dividend Overview

Get Disc Medicine Inc. Data in Excel

Get Disc Medicine Inc. Data in Excel